Leadership

The US Association for Accessible Medicines has named Lupin’s Bob Hoffman as its new chair. Meanwhile, departures have been seen at Stada and Dr Reddy’s, among other industry management changes.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Biogen’s head of development reflects on transforming company strategy, surviving the Aduhelm crisis and building sustainable growth through disciplined portfolio management.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Following a rebrand in 2024 with a mission to expand to global markets, Latvia’s Olpha has started shipping cholesterol management drugs to Mexico after winning a government supply tender.

Atul Gupta, MD and CMO of Royal Philips’ Diagnosis & Treatment business, shares his views about potential developments in imaging and wider medtech in 2026 and the value of AI. He warns that clinicians will not adopt AI they don’t trust, understand or find helpful in real-world conditions.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

CEO Jean-Christophe Tellier tells attendees at the San Francisco meeting that there is much more to come from Bimzelx.

From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.

CEO Vas Narasimhan told attendees at J.P. Morgan that the firm’s considerable financial firepower means it will continue to do “value-creating bolt-ons like you saw last year."